SNDL INC (SNDL) Stock Fundamental Analysis
NASDAQ:SNDL - CA83307B1013 - Common Stock
2.25 USD
+0.01 (+0.45%)
2.2599 USD
+0.01 (+0.44%)
SNDL gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. SNDL has a great financial health rating, but its profitability evaluates not so good. SNDL has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
SNDL had negative earnings in the past year.
SNDL had a positive operating cash flow in the past year.
SNDL had negative earnings in each of the past 5 years.
SNDL had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
SNDL has a better Return On Assets (-7.60%) than 70.47% of its industry peers.
SNDL has a Return On Equity of -9.03%. This is in the better half of the industry: SNDL outperforms 75.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.6% | ||
| ROE | -9.03% | ||
| ROIC | N/A |
ROA(3y)-13.41%
ROA(5y)-27.04%
ROE(3y)-16.09%
ROE(5y)-30.65%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 27.11%, SNDL perfoms like the industry average, outperforming 53.37% of the companies in the same industry.
SNDL's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for SNDL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 27.11% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y38.61%
GM growth 5Y-0.23%
2. Health
2.1 Basic Checks
SNDL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SNDL has about the same amount of shares outstanding.
The number of shares outstanding for SNDL has been increased compared to 5 years ago.
Compared to 1 year ago, SNDL has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 1.96 indicates that SNDL is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 1.96, SNDL is in the better half of the industry, outperforming 64.77% of the companies in the same industry.
The Debt to FCF ratio of SNDL is 3.03, which is a good value as it means it would take SNDL, 3.03 years of fcf income to pay off all of its debts.
SNDL has a Debt to FCF ratio of 3.03. This is amongst the best in the industry. SNDL outperforms 89.12% of its industry peers.
A Debt/Equity ratio of 0.11 indicates that SNDL is not too dependend on debt financing.
SNDL's Debt to Equity ratio of 0.11 is in line compared to the rest of the industry. SNDL outperforms 50.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 1.96 |
ROIC/WACCN/A
WACC9.05%
2.3 Liquidity
SNDL has a Current Ratio of 5.03. This indicates that SNDL is financially healthy and has no problem in meeting its short term obligations.
SNDL has a better Current ratio (5.03) than 71.50% of its industry peers.
A Quick Ratio of 3.36 indicates that SNDL has no problem at all paying its short term obligations.
SNDL has a Quick ratio of 3.36. This is in the better half of the industry: SNDL outperforms 61.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.03 | ||
| Quick Ratio | 3.36 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 13.14% over the past year.
The Revenue has been growing slightly by 3.54% in the past year.
Measured over the past years, SNDL shows a very strong growth in Revenue. The Revenue has been growing by 70.65% on average per year.
EPS 1Y (TTM)13.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150.23%
Revenue 1Y (TTM)3.54%
Revenue growth 3Y154.1%
Revenue growth 5Y70.65%
Sales Q2Q%7.3%
3.2 Future
Based on estimates for the next years, SNDL will show a very strong growth in Earnings Per Share. The EPS will grow by 42.75% on average per year.
The Revenue is expected to grow by 5.10% on average over the next years.
EPS Next Y81.82%
EPS Next 2Y43.55%
EPS Next 3Y33.21%
EPS Next 5Y42.75%
Revenue Next Year4.31%
Revenue Next 2Y4.2%
Revenue Next 3Y4.71%
Revenue Next 5Y5.1%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SNDL. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 306.92, SNDL can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SNDL indicates a somewhat cheap valuation: SNDL is cheaper than 65.80% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.81. SNDL is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 306.92 |
4.2 Price Multiples
SNDL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. SNDL is cheaper than 81.35% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, SNDL is valued cheaply inside the industry as 84.46% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.2 | ||
| EV/EBITDA | 16.46 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
SNDL's earnings are expected to grow with 33.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.55%
EPS Next 3Y33.21%
5. Dividend
5.1 Amount
SNDL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2.25
+0.01 (+0.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners16.26%
Inst Owner Change6.55%
Ins Owners4.32%
Ins Owner ChangeN/A
Market Cap579.04M
Analysts82.86
Price Target7.14 (217.33%)
Short Float %1.28%
Short Ratio1.07
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)91.42%
Min EPS beat(2)63.24%
Max EPS beat(2)119.61%
EPS beat(4)3
Avg EPS beat(4)122.67%
Min EPS beat(4)-37.25%
Max EPS beat(4)345.1%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.36%
Min Revenue beat(2)-6.38%
Max Revenue beat(2)3.66%
Revenue beat(4)2
Avg Revenue beat(4)-0.24%
Min Revenue beat(4)-6.38%
Max Revenue beat(4)3.66%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)100%
PT rev (3m)100%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-20%
EPS NY rev (3m)-20%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.78%
Revenue NY rev (3m)0.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 306.92 | ||
| P/S | 0.85 | ||
| P/FCF | 16.2 | ||
| P/OCF | 13.25 | ||
| P/B | 0.74 | ||
| P/tB | 0.89 | ||
| EV/EBITDA | 16.46 |
EPS(TTM)-0.03
EYN/A
EPS(NY)0.01
Fwd EY0.33%
FCF(TTM)0.14
FCFY6.17%
OCF(TTM)0.17
OCFY7.55%
SpS2.64
BVpS3.04
TBVpS2.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.6% | ||
| ROE | -9.03% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 27.11% | ||
| FCFM | 5.27% |
ROA(3y)-13.41%
ROA(5y)-27.04%
ROE(3y)-16.09%
ROE(5y)-30.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y38.61%
GM growth 5Y-0.23%
F-Score7
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 3.03 | ||
| Debt/EBITDA | 2.6 | ||
| Cap/Depr | 19.75% | ||
| Cap/Sales | 1.17% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 135.06% | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.03 | ||
| Quick Ratio | 3.36 | ||
| Altman-Z | 1.96 |
F-Score7
WACC9.05%
ROIC/WACCN/A
Cap/Depr(3y)18.2%
Cap/Depr(5y)23.85%
Cap/Sales(3y)1.2%
Cap/Sales(5y)3.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150.23%
EPS Next Y81.82%
EPS Next 2Y43.55%
EPS Next 3Y33.21%
EPS Next 5Y42.75%
Revenue 1Y (TTM)3.54%
Revenue growth 3Y154.1%
Revenue growth 5Y70.65%
Sales Q2Q%7.3%
Revenue Next Year4.31%
Revenue Next 2Y4.2%
Revenue Next 3Y4.71%
Revenue Next 5Y5.1%
EBIT growth 1Y76.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year108.49%
EBIT Next 3Y150.28%
EBIT Next 5Y93%
FCF growth 1Y268.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y397.24%
OCF growth 3YN/A
OCF growth 5YN/A